CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 70 enrolled
Drug / intervention
valacyclovirdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00306293
NCT00306293Phase 4Completed
CompareCT.gov

The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection

GlaxoSmithKline·interventional·Posted Mar 23, 2006·Updated Mar 23, 2018

In Brief

A Phase 4 clinical trial evaluating valacyclovir for Herpes Labialis. Completed, enrolled 70 participants across 18 sites.

Detailed Summary

Eligible subjects will be randomized to receive VALTREX 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days in between.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Labialis
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 23, 2006
Enrollment StartFeb 20, 2006
Primary CompletionNov 27, 2006
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 20.3 years ago

Interventions

valacyclovirdrug

valacyclovir